1	Primary exposure to Zika virus increases risk of symptomatic dengue virus infection with
2	serotypes 2, 3, and 4 but not serotype 1
3	
4	Jose Victor Zambrana <sup>1,2</sup> <sup>†</sup> , Chloe M. Hasund <sup>3</sup> <sup>†</sup> , Rosemary A. Aogo <sup>3</sup> <sup>†</sup> , Sandra Bos <sup>4</sup> , Sonia
5	Arguello <sup>1</sup> , Karla Gonzalez <sup>1,5</sup> , Damaris Collado <sup>1</sup> , Tatiana Miranda <sup>1</sup> , Guillermina Kuan <sup>1,6</sup> , Aubree
6	Gordon <sup>2</sup> , Angel Balmaseda <sup>1,5</sup> , Leah Katzelnick <sup>3*</sup> , Eva Harris <sup>4*</sup>
7	<sup>†</sup> These authors contributed equally.
8	*Co-corresponding authors. Leah Katzelnick (leah.katzelnick@nih.gov) and Eva Harris
9	(eharris@berkeley.edu).
10	
11	<sup>1</sup> Sustainable Sciences Institute; Managua, Nicaragua
12	<sup>2</sup> Department of Epidemiology, School of Public Health, University of Michigan; Ann Arbor, MI,
13	USA
14	<sup>3</sup> Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of
15	Allergy and Infectious Diseases, National Institutes of Health, Bethesda; MD, USA
16	<sup>4</sup> Division of Infectious Disease and Vaccinology, School of Public Health, University of
17	California, Berkeley; Berkeley, CA, USA
18	<sup>5</sup> Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de
19	Salud; Managua, Nicaragua
20	<sup>6</sup> Centro de Salud Sócrates Flores Vivas, Ministerio de Salud; Managua, Nicaragua
21	
22	One-Sentence Summary: Dengue disease risk is differentially modulated depending on pre-
23	existing immunity to dengue and Zika virus infections and the secondary infecting serotype.
24	

#### 25 ABSTRACT

Infection with any of the four dengue virus serotypes (DENV1-4) can protect against or enhance 26 subsequent dengue depending on pre-existing antibodies and the subsequent infecting serotype. 27 Additionally, primary infection with the related flavivirus Zika virus (ZIKV) has been shown to 28 increase DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced 29 risk of disease caused by all four serotypes in a pediatric Nicaraguan cohort. Of 3,412 30 participants in 2022, 10.6% experienced symptomatic DENV infections caused by DENV1 31 (n=139), DENV4 (n=133), DENV3 (n=54), DENV2 (n=9), or an undetermined serotype (n=39). 32 33 Longitudinal clinical and serological data were used to define infection histories, and generalized linear and additive models adjusted for age, sex, time since the last infection, cohort year, and 34 repeat measurements were used to predict disease risk. Compared to flavivirus-naïve 35 participants, primary ZIKV infection increased disease risk of DENV4 (relative risk = 2.62, 95% 36 confidence interval: 1.48-4.63) and DENV3 (2.90, 1.34-6.27) but not DENV1 (1.20, 0.72-1.99). 37 Primary DENV infection or a DENV followed by ZIKV infection also increased DENV4 risk. 38 39 We re-analyzed 19 years of cohort data and demonstrated that prior flavivirus-immunity and preexisting antibody titer differentially affected disease risk for incoming serotypes, increasing risk 40 of DENV2 and DENV4, protecting against DENV1, and protecting at high titers but enhancing 41 at low titers against DENV3. We thus find that prior ZIKV infection, like prior DENV infection, 42 increases risk of certain DENV serotypes. Cross-reactivity among flaviviruses should be 43 44 carefully considered when assessing vaccine safety and efficacy.

#### 45 **INTRODUCTION**

Dengue virus, comprised of four distinct serotypes (DENV1-4), and Zika virus (ZIKV) are antigenically related, mosquito-borne flaviviruses that cause a significant global health burden (1-3). Both flaviviruses are transmitted by female *Aedes aegypti* mosquitoes, co-circulate in many countries, and cause major epidemics worldwide (1). DENV and ZIKV infection each induce antibodies that cross-react with the other viruses, but how these antibodies modulate subsequent disease risk has only been partially elucidated (4, 5).

52

53 Following a DENV or ZIKV infection, neutralizing antibodies at high titers are observed to provide long-lasting protection against the infecting virus, a phenomenon termed homotypic 54 protection (6). Cross-reactive neutralizing antibodies can provide protection against an incoming 55 heterotypic infection (7-9). However, DENV infection also elicits low-to-intermediate cross-56 reactive antibody titers, which can increase risk of a symptomatic infection and enhance disease 57 severity in a subsequent DENV infection with a different serotype (10-13). This increased risk 58 has been attributed to a phenomenon known as antibody-dependent enhancement (ADE), 59 whereby non- or poorly neutralizing antibodies facilitate DENV entry into host cells through the 60 61 Fcy receptor, improving infection efficiency and activating target immune cells (14, 15). Increased risk of future dengue disease severity following a DENV infection is well established 62 (11, 14, 16), and two studies have reported an association between prior ZIKV infection and 63 DENV2 disease risk (17, 18). This last finding is consistent with studies in macaques exposed to 64 ZIKV and then DENV2, which have shown an increase in viremia compared to ZIKV-naïve 65 66 macaques (19, 20). It is unclear whether primary ZIKV infection modulates secondary dengue caused by other serotypes. 67

68

Symptomatic and severe disease occur more frequently in secondary DENV2 and DENV4 infections, as compared to DENV1 and DENV3 infections (10, 11, 21-24). In line with this observation, a higher neutralizing antibody titer is needed to protect against symptomatic DENV2 versus other serotypes (9, 23, 25). We previously showed that a broad range of pre-existing anti-DENV binding antibody titers can enhance DENV2 disease, low titers can enhance DENV3, and high titers protect against DENV1 and DENV3 (26). Less is known about the effect of pre-existing antibody titer on DENV4.

76

In 2022, all four DENV serotypes co-circulated in Nicaragua in populations affected by the 2016 77 Zika epidemic. This large dengue epidemic (n=374 cases) in the Nicaraguan Pediatric Cohort 78 79 Study enabled us to evaluate whether prior ZIKV and DENV infections modulate risk of secondary dengue caused by DENV1, DENV3, or DENV4. We also evaluated whether 80 individuals with a prior DENV infection followed by a ZIKV infection (DENV-ZIKV) had 81 82 similar outcomes as individuals with a primary ZIKV infection followed by DENV infection (ZIKV-DENV), a group observed for the first time in the Nicaraguan cohort. Further, we 83 measured the effect of flavivirus immunity and pre-existing DENV antibody titers on 84 symptomatic DENV1-4 infection over 19 years of cohort data and performed a mediation 85 analysis to examine the relative contribution of antibody titer to the relationship between 86 infection history and DENV infection outcome. Finally, we evaluated the long-term antibody 87 kinetics in individuals with varied flavivirus infection histories. 88

89

#### 91 **RESULTS**

## All four DENV serotypes co-circulated during the 2022-2023 dengue epidemic in Nicaragua, and prior DENV or ZIKV infections increase risk of dengue cases

The Pediatric Dengue Cohort Study has followed ~4,000 participants ages 2-17 years for 94 arbovirus infection in Managua, Nicaragua, continuously since 2004 (table S1). In 2022, for the 95 first time since the cohort was established, all four DENV serotypes were detected in cases, 96 circulating simultaneously (Fig. 1A). A total of 10.6% of all participants experienced 97 symptomatic DENV infections; 374 cases met the dengue case definition and were confirmed by 98 99 RT-PCR or paired acute and convalescent serology of the 3,412 active cohort participants with complete infection histories. Most infections were caused by DENV1 (n=139) and DENV4 100 (n=133), followed by DENV3 (n=54) and DENV2 (n=9), and a subset were confirmed by 101 102 serology (n=39) (Table 1).

103

Before the 2022-2023 epidemic in Nicaragua, the ZIKV pandemic affected the cohort in 2016, 104 105 followed by a large DENV2 epidemic in 2019, with minimal flavivirus circulation observed between these epidemics. Further, DENV2 was the only serotype detected in cases between 2014 106 107 and 2021. Thus, based on the young ages of the cohort, nearly half of participants (n=48.6%) were only ever exposed to ZIKV or DENV2. In 2022, 45.7% of the cohort were flavivirus-naïve, 108 21.7% had experienced only a prior ZIKV infection, 8.8% had only had one prior DENV 109 110 infection, and 23.8% had experienced different combinations of DENV and ZIKV infections (Fig. 1B). Notably, DENV seropositivity and population anti-DENV antibody titers declined 111 after the DENV3 epidemic in 2010-2011, titers increased after the ZIKV epidemic in 2016, and 112 113 seropositivity and titers increased again after the DENV2 epidemic in 2019-2020 (Fig. 1B and

114 1C).

115

116	During the 2022-2023 dengue epidemic, the overall risk of experiencing a dengue case was 7.8%
117	(6.7%-9.4%) for the flavivirus-naïve group, our reference group, and was significantly higher for
118	participants with one prior ZIKV infection (risk = 14.8%, 12.5%-17.6%), two prior DENV
119	infections (DENV-DENV) (19.0, 11.4%-31.7%), and one prior DENV and then ZIKV infection
120	(DENV-ZIKV) (14.4%, 10.0%-20.7%) (fig. S1). We were unable to calculate risk for some of
121	the more complex infection histories, including those with different sequences of DENV and
122	ZIKV infections followed by DENV infection (DENV-ZIKV-2+DENV, ZIKV-DENV-DENV,
123	and 2+DENV-ZIKV-DENV), because of low numbers of individuals in these groups and lack of
124	any symptomatic DENV infections.

125

# Primary DENV and ZIKV infection increases risk of symptomatic infection caused by DENV2 and DENV4 but not DENV1, while primary ZIKV infection also increases risk of symptomatic DENV3 infection

To investigate the role of infection history on outcome by serotype, we first evaluated whether 129 primary ZIKV infection increased the risk of symptomatic infections caused by DENV1, 130 DENV3, and DENV4 during the 2022-2023 epidemic. Only 9 DENV2 cases were detected in 131 2022, thus we could not analyze DENV2 case risk by infection histories. Using log-binomial 132 generalized linear models (GLMs) adjusted for age, sex, and time since previous infection, we 133 found that primary ZIKV infection significantly increased the risk of symptomatic DENV 134 infection compared to flavivirus-naïve individuals (Risk Ratio (RR) = 1.61, 95% CI: 1.20-2.17). 135 136 When these analyses were stratified by infecting serotype, risk of disease was increased for

DENV3 (RR = 2.90, 1.34-6.27) and DENV4 (RR = 2.62, 1.48-4.63), but not DENV1 (Fig. 2A and table S2). Children with a prior ZIKV infection also trended toward increased risk of dengue with warning signs or severe dengue (DwWS/SD) (RR=2.19, 0.99: 4.83, p = 0.053) compared to flavivirus-naïve children.

141

To increase statistical power and resolution and to include DENV2, we performed the above 142 analyses on data from the entire Pediatric Dengue Cohort Study timeframe (2004 to 2023). We 143 used both log-binomial and log-poisson generalized linear mixed-effect models (GLMMs) 144 145 adjusted for age, sex, time since last infection, and cohort epidemic year, with clustering at the individual level to account for repeat measurements. Similar to observations for the 2022-2023 146 epidemic, we found that compared to flavivirus-naïve individuals, a prior ZIKV infection 147 significantly increased the risk of symptomatic dengue overall (RR=1.87, 1.54-2.27) as well as 148 the risk of DwWS/SD (RR = 3.62, 2.44-5.38) (Fig. 2B and table S3). Primary ZIKV infection 149 significantly increased the risk for a subsequent DENV2, DENV3, and DENV4 infection, but not 150 151 DENV1.

152

We performed the same analyses for participants with primary DENV infection. When analyzed across cohort years, primary DENV infection significantly increased the risk of symptomatic DENV2 (RR = 2.09, 1.44-3.05) and DENV4 (RR = 3.28, 1.64-6.57) infections, but not DENV1 or DENV3 infections (Fig. 2B and table S3). Unlike a prior ZIKV infection, a single prior DENV infection did not increase risk of symptomatic dengue overall (RR = 1.17, 0.94-1.45); however, one prior DENV infection did increase overall risk of DwWS/SD (RR = 1.67, 1.09-2.57), although not as much as prior ZIKV (Fig. 2B and table S3).

160

### The number and order of DENV and ZIKV infections determine risk of developing future dengue

Sequential infection with different DENV serotypes is thought to protect against disease by 163 inducing broadly protective antibodies against all serotypes (27). We previously found that 164 individuals with primary DENV infection followed by a ZIKV infection (DENV-ZIKV) were at 165 increased risk of subsequent symptomatic DENV2 infection compared to being flavivirus-naïve, 166 suggesting that the additional ZIKV infection did not broaden their protective immunity (26). 167 168 Here, we compared dengue disease risk for DENV-ZIKV infection histories to children with a previously unobserved sequence of infections: ZIKV followed by one DENV infection (ZIKV-169 DENV). In the analysis of all epidemic seasons, the DENV-ZIKV infection history was found to 170 significantly increase the risk of subsequent symptomatic dengue overall (RR = 1.47, 1.09-1.99) 171 and specifically, subsequent symptomatic infection with DENV2 (RR = 2.53, 1.64-3.91) and 172 DENV4 (RR = 4.05, 1.93-8.49), as well as DwWS/SD (RR = 3.26, 1.94-5.50) (Fig. 2B and table 173 174 S3). In contrast, the ZIKV-DENV infection sequence did not increase the risk of future symptomatic DENV1-4 infections, dengue disease, or DwWS/SD (Fig. 2A and 2B, table S2 and 175 S3). 176

177

Counter to our expectation, we also found that across epidemic seasons, those with two prior DENV infections (DENV-DENV) were at increased risk of subsequent symptomatic dengue overall (RR=2.66, 1.49-4.76) and DwWS/SD (3.62, 2.44-5.38) compared to the flavivirus-naïve group (Fig. 2A and 2B, tables S2 and S3). The DENV-DENV group was also at a greater risk of symptomatic DENV3 infection (RR = 2.40, 1.37-4.23) (Fig. 2B and table S3). However, those

183 with two or more DENV infections (2+DENV group) or at least two DENV infections and a ZIKV infection (2+DENV-ZIKV) were not at increased risk of either symptomatic or severe 184 dengue (Fig. 2B and table S3). Protective effects were only observed for the 2+ DENV group 185 against symptomatic DENV infection overall (RR = 0.64, 0.48-0.86), and DENV1 (RR = 0.41, 186 0.22-0.79). Individuals with multiple flavivirus infections may live in high-risk areas for 187 188 exposure to DENV. We thus performed a sensitivity analysis where we controlled for the ageadjusted DENV seroprevalence at the neighborhood level in the year prior to the recorded 189 dengue case for each participant and clustered participants by neighborhood. Results were 190 191 similar to our previous results (Fig. 2) for both the 2022-2023 epidemic season and the complete cohort epidemic seasons (2004-2023) across infection histories, suggesting that spatial risk did 192 not explain the increased risk of disease observed for the DENV-DENV group (fig. S2). 193

194

We investigated when the 12 individuals with dengue cases in 2022-2023 in the DENV-DENV 195 group experienced their previous infection to determine the likely prior infecting serotype. Most 196 197 of those with tertiary DENV4 cases had their second infection three years previously, during the 198 DENV2 epidemic, whereas most DENV1 tertiary cases had experienced their second infection in 2021, right before 2022 epidemic when multiple serotypes may have already been circulating 199 (fig. S3). While some sequential infections detected by DENV iELISA in previous years may 200 have been due to homotypic re-exposure, the epidemiology of dengue in the cohort makes it 201 202 likely that those experiencing tertiary infections in 2022-2023 were infected with distinct serotypes. 203

204

205 Of note, consistent with previous findings, older age was a significant risk factor for dengue

disease as well as for symptomatic DENV1, DENV2 and DENV4 infections in the full cohort analysis. Sex was not a significant factor except with DENV4, where male sex was associated with reduced risk of symptomatic infection in both analyses (Fig. 2A and 2B). Time since infection was not a significant risk factor in any model, except for a slightly increased risk of DENV3 in the complete cohort analysis (Fig. 2A and 2B).

211

### Pre-existing flavivirus immunity and antibody titers protect against DENV1, but can increase risk of DENV2, DENV3, and DENV4

Across infection histories, we observed increased risk of DENV2, DENV3, and DENV4 disease 214 and DwWS/SD and protective effects against symptomatic DENV1 infection, comparing to 215 flavivirus-naïve individuals. To explore how overall flavivirus immunity affected disease caused 216 217 by each serotype, we grouped individuals with any prior DENV or ZIKV infection, regardless of serotype or number of infections, as "flavivirus-immune" and the non-exposed as "flavivirus-218 naïve." Compared to flavivirus-naïve individuals, those who were flavivirus-immune were at 219 220 significantly increased risk of dengue disease (p = < 0.001), DwWS/SD (p = < 0.001), and DHF/DSS (p = < 0.001) (Fig. 3 and table S4). However, distinct risks were observed for different 221 serotypes, with significant risk for flavivirus-immune participants of DENV2 (p = < 0.001) and 222 DENV4 disease (p=0.002), but not DENV3 (p=0.551). Conversely, flavivirus-immune 223 individuals were at significantly lower risk of DENV1 (p=0.036), indicating protection (Fig. 3) 224 225 and table S5).

226

We previously showed that pre-existing antibodies, as measured by iELISA (*12*), can protect or enhance dengue disease and disease severity depending on the titer magnitude and secondary

infecting serotype (12, 26). With the recent circulation of DENV4 in the region, we were also 229 able to test how pre-existing anti-flavivirus antibodies modulate all four serotypes, both for the 230 2022 epidemic (Fig. 4A) and across all cohort years (Fig. 4B). Here, we found that DENV 231 iELISA titers (except those >1280) significantly increased risk of symptomatic DENV4 infection 232 compared to flavivirus-naïve children. This effect paralleled that seen for DENV2 in our full 233 cohort analyses. The pattern was different for DENV3, where low titers (<21) increased disease 234 (p=0.005) while high titers were protective in the full cohort analyses. Finally, no enhancing 235 effects were observed against DENV1, while higher titers of pre-existing anti-DENV antibodies 236 237 were protective (p=0.041), as seen against DENV3 (Fig. 4A and table S3). Regarding the overall risk of dengue disease and DwWS/SD, we found that low iELISA titers were associated with 238 increased risk of both symptomatic DENV infection and DwWS/SD (Fig. 4 A and B, table S5 239 and S6). 240

241

#### 242 Antibody titers strongly explain the relationship between infection history and dengue risk

Based on our observations, we hypothesized that the effect of specific DENV and ZIKV 243 infection histories on the risk of dengue is partially mediated (i.e., explained by) pre-existing 244 DENV iELISA titers. Using a well-established approach, the mediation model, we tested the 245 degree to which each infection history influences dengue disease outcome 1) directly, meaning 246 the infection history itself affected outcome, versus 2) indirectly, meaning infection history 247 248 modified antibody titers, which in turn modulated disease outcome. We analyzed the 2022-2023 epidemic season, and our models were adjusted for time since last infection, age, and sex. We 249 separately tested the mediating effect of iELISA titers within a range previously identified as 250 251 enhancing (10-320 vs. lower or higher titers) as opposed to protective (>320 vs. <320).

252 Consistently, every infection history induced antibodies in the range of 10-320 that were associated with increased risk of dengue (Fig. 5A). Titers between 10-320 explained a smaller 253 fraction (<25%) of the total effect of DENV-DENV, ZIKV-DENV and 2+DENV infection 254 histories on dengue outcome, while antibodies in this range explained a larger fraction of the 255 effect of DENV, DENV-immune, ZIKV, DENV-ZIKV, and 2+DENV-ZIKV infection histories 256 (Fig. 5A). Additionally, ZIKV infection had a direct effect (independent of titer) on increasing 257 dengue risk, while the 2+DENV history had a direct protective effect. Conversely, when we 258 tested whether titers greater than 320 (as compared to lower titers) mediated the relationship 259 260 between infection history and dengue outcome, we found that high antibody titers showed a trend toward protection against symptomatic DENV infection, although this effect was not 261 significant. High antibody titers explained almost all of the effect on dengue outcome for ZIKV-262 DENV history and almost none of the effect for the ZIKV group, while for other histories, titer 263 explained about a quarter of the effect (Fig. 5B). ZIKV, DENV-DENV, and DENV-ZIKV still 264 retained direct effects on increasing dengue risk. Notably, for infection histories that predisposed 265 individuals to a greater risk of symptomatic DENV infection, such as DENV-DENV, high 266 antibodies decreased their risk probabilities, although not significantly (Fig. 5B). On the 267 contrary, for those categories with less risk, including 2+DENV or ZIKV-DENV, antibodies 268 increased protection against symptomatic DENV infection (Fig. 5B). 269

270

#### 271 Order of infecting DENV and ZIKV infections modifies antibody magnitude and kinetics

272 Cross-reactive anti-DENV antibody titers are modulated both by time since last infection and 273 infection history. We have previously shown that anti-DENV antibodies measured by the DENV 274 iELISA are stable or increase over time after a primary DENV and ZIKV infection and wane

275 after secondary DENV or sequential DENV and ZIKV infections (28). Here, we characterized the magnitude and kinetics of anti-DENV antibodies in previously reported infection histories 276 (28), and for the first time, in individuals with ZIKV-DENV infection histories. We noted 277 differences in the magnitude of the iELISA antibody response measured in the annual sample 278 after infection. Primary ZIKV infection induced the lowest antibody titers, followed by a primary 279 DENV infection (Fig. 6 and table S6). Interestingly, the ZIKV-DENV group on average had 1.1-280 fold higher titers (p=3.2e-10) than the DENV-ZIKV group at the same timepoint (Fig. 6 and 281 table S7), suggesting order of infection has a modest effect on the magnitude of cross-reactive 282 anti-DENV antibodies. After a primary ZIKV infection, antibodies increased (half-life, t<sub>1/2</sub>: 2.31 283 years, 95% CI: 2.10-2.48) for three years, and then gradually declined ( $t_{1/2}$ : 3.65 years, 3.01-284 4.33), whereas after a primary DENV infections antibodies were stable (Fig. 6 and table S7). We 285 also found that after sequential DENV or DENV and ZIKV infections, on average, antibodies 286 initially wane rapidly in the first  $\sim 2$  years, with a subsequent gradual waning or stabilization. In 287 particular, the ZIKV-DENV group was still experiencing rapid waning at the last timepoint 288 measured, suggesting this infection history may be less protective long-term if their antibodies 289 continue to wane. 290

291

292

#### 293 **DISCUSSION**

Our study presents novel insights into the complex interplay between the immune responses to DENV and ZIKV infections and their clinical and epidemiological outcomes. To our knowledge, this is the first study in humans to demonstrate that primary ZIKV infection increases risk of subsequent dengue disease in a serotype-dependent manner. We also show that DENV-ZIKV

infection histories are associated with increased risk of symptomatic DENV2 and DENV4 infection, while ZIKV-DENV infection history is not. Pre-existing antibody titers were found to modulate disease risk depending on the incoming serotype. Finally, we show that most infection histories can elicit both enhancing and protective antibodies, and their relationship to DENV infection outcome is strongly dependent on antibody titer.

303

We have previously shown that a prior ZIKV infection increased risk of symptomatic and severe 304 DENV2 (26). Here, using data from 374 cases in the 2022-2023 epidemic, we show that primary 305 306 ZIKV infection also increased the risk of symptomatic DENV3 and DENV4 infections and overall disease severity. Intriguingly, a prior ZIKV infection was not a risk factor for 307 symptomatic DENV1 infection. This matched our analysis showing that primary DENV 308 infection is a risk factor for severe disease and symptomatic DENV2 and DENV4 infections 309 across all cohort years. The enhancing effect of ZIKV has now been observed in two separate 310 epidemics and against multiple DENV serotypes in Nicaragua. A separate study in Brazil of 879 311 dengue cases, >99% of which were caused by DENV2, similarly found that individuals with only 312 prior ZIKV infection were more likely to experience severe disease and hospitalization than 313 314 flavivirus-naïve participants (17). In this study, the authors found that the primary ZIKV group did not have higher viremia or pro-inflammatory cytokines than the DENV group, leading them 315 to propose that the mechanism of enhanced severity may differ from classical ADE. Collectively, 316 317 these observations suggest that induction of primary ZIKV immunity may increase risk of future dengue disease, posing a potential challenge to development of Zika vaccines. 318

319

320 Our study also shows that the order of sequential DENV and ZIKV infections modulates future

321 disease outcome. DENV followed by ZIKV infection increased the risk of a symptomatic and severe DENV infection, whereas ZIKV followed by DENV infection did not. When stratified by 322 incoming serotype, we found that DENV-ZIKV infection histories increased the risk only for 323 DENV2 and DENV4, again showing immunological similarities in secondary DENV infections 324 by these two viruses. A study in macaques has similarly found that DENV-ZIKV sequence 325 326 produced an inferior immune response compared to ZIKV-DENV exposed monkeys, impacting the quality of antibodies produced in response to tertiary DENV infection and the magnitude of 327 recall memory immune response, suggesting important differences by sequential order of 328 329 infection (19, 29, 30). Notably, a study in Sri Lanka showed that individuals with prior DENV and ZIKV infection histories or only prior DENV infection experience increased risk of plasma 330 leakage, shock, and severe dengue compared to flavivirus-naïve individuals, although order of 331 infections could not be determined (31). 332

333

Interestingly, we found that having had two prior DENV infections was a significant risk factor 334 for subsequent symptomatic and severe DENV infections as well as DENV3 symptomatic 335 infection. However, we did not observe increased disease risk in groups with at least two prior 336 DENV infections, with or without subsequent ZIKV infection (2+DENV and 2+DENV-ZIKV), 337 and protective effects were observed for the 2+DENV group against any dengue case and 338 symptomatic DENV1 infection. These groups include some individuals who entered the study 339 340 with detectable anti-DENV antibodies and then experienced at least one DENV infection, meaning that some may have had only two prior infections. One interpretation of these findings 341 is that there is something distinct about the DENV-DENV group, which constitutes a small 342 343 fraction of the overall cohort. They may be at higher risk for exposure, although our

neighborhood level analyses did not support this hypothesis. Alternatively, these findings may 344 suggest that two DENV infections are not always be enough to provide broad protection against 345 symptomatic DENV infection. Prior work has suggested that tertiary infections are rare in 346 hospital settings (32, 33). Here we report mild-to-severe tertiary infections, as our community-347 based cohort allowed us to capture a greater spectrum of the disease. Our results are consistent 348 349 with prior reports from the Pediatric Dengue Cohort Study that tertiary infections for some epidemic years were more likely to be symptomatic than inapparent (34). Although we 350 previously found that having two or more DENV infections protected against DENV2 cases 351 352 during the 2019-2020 epidemic, DENV2 had circulated in the years before that epidemic, implying that one of the prior infections may have been with DENV2 and thus that homotypic 353 immunity contributed to reduced risk (35, 36). In contrast, DENV1 and DENV3 have not 354 circulated appreciably in Nicaragua for more than 10 years, and our pediatric study population 355 had never experienced a large DENV4 epidemic. Lack of homotypic immunity against these 356 serotypes and insufficient heterotypic immunity may have driven the explosive dengue epidemic 357 in 2022-2023 and explained the lack of protection even in those with two prior DENV infections. 358

359

Our findings also support the previous observation that pre-existing DENV immunity differentially modulates subsequent symptomatic and severe disease depending on infecting serotype. We previously showed that low-to-intermediate pre-existing DENV iELISA antibody titers were associated with increased symptomatic and severe DENV2 and DENV3 disease, whereas high titers were protective against DENV1 and DENV3 (*26*). Here, we found that a history of any flavivirus infection increased the risk of future DwWS/SD and DHF/DSS as well as dengue cases caused by DENV2 and DENV4, but was protective against DENV1 and had

neutral risk against DENV3. Low-to-intermediate pre-existing antibody titers increased risk of 367 DENV2 and DENV4 infections compared to flavivirus-naïve individuals, and high titers were 368 not associated with increased risk nor protection. In contrast, high pre-existing antibodies 369 reduced risk of symptomatic DENV1 and DENV3 infections, while low titers were associated 370 with increased risk of symptomatic DENV3 infection. Structural differences between the viruses 371 372 may explain a lower probability of ADE with DENV1, which is associated with lower frequency of symptomatic and severe secondary infections (37). DENV1 has been shown to produce more 373 mature viral particles *in vivo*, which are poorly neutralized by fusion loop antibodies, and it has 374 375 been shown in vitro that some DENV1 particles breathe less compared to other serotypes (38, 39). 376

377

We also showed that anti-DENV antibodies help mediate the relationship between DENV or 378 ZIKV infection and risk of subsequent symptomatic DENV infection via antibodies. Across 379 infection histories, we found that DENV iELISA antibody titers are good predictors of disease 380 outcome. This observation is consistent with previous studies showing that high anti-DENV 381 antibody titers are good correlates of protection following vaccination with dengue candidate 382 383 CYD-TDV, while a lower titer was a correlate of risk (40). Notably, some infection histories still retain direct effects, suggesting that there are differences in the quality of immunity that are not 384 fully captured by our measure of anti-DENV antibodies. 385

386

Prior work has suggested that cross-reactive protection against DENV wanes within one to three years post-infection, and a longer time between sequential DENV infections increases the probability of symptomatic DENV infections (*32*, *34*, *41*, *42*). Our previous work showed that

390 cross-reactive antibodies after a primary DENV infection are stable by about 6 months, while primary ZIKV infection elicits cross-reactive DENV antibodies that increased over time up to 391 three years (28). In contrast, after secondary DENV or DENV-ZIKV infection, we observed 392 high antibodies followed by long-term decay. Here, we show that after 3 years, DENV cross-393 reactive antibodies in primary ZIKV participants begin to decay. We also showed that the ZIKV-394 395 DENV group elicited slightly higher DENV iELISA titer than the DENV-ZIKV group did, suggesting broader immunity, which could have resulted in a reduction of risk for a subsequent 396 symptomatic DENV infection. However, the ZIKV-DENV group experienced rapid antibody 397 398 decay, raising the possibility that the protective effect may not be long-lived.

399

Our study has several strengths, including a robust study design that has been sustained over 19 400 years. This extensive period of observation has enabled us to detect epidemics of all DENV 401 serotypes and ZIKV, encompassing the entire spectrum of disease severity, from inapparent to 402 symptomatic and severe infections. This comprehensive dataset allows the capture of detailed 403 arboviral infection histories, including single and sequential DENV and ZIKV infections, with a 404 large sample size. Nonetheless, our study has several limitations. The data is derived from a 405 406 Nicaraguan cohort, and the results may not generalize to other settings with different DENV and ZIKV strains as well as other circulating flaviviruses. However, given the similarity in dengue 407 epidemiology across the Americas, our findings will likely have broader applicability in the 408 409 region (43-45). Additionally, the exact sequence of infecting DENV serotypes is not recorded 410 due to a lack of serotype information of inapparent infections. The sequence of infecting DENV serotypes may modulate disease outcome in ways we could not account for here. Further, risk 411 412 calculations using all Pediatric Dengue Cohort Study participants in the denominator assumes

risk is homogenous, which is implausible. To account for this, we adjusted results by prior year DENV seroprevalence at the neighborhood levels as a proxy for spatial risk and showed that our results did not qualitatively change. Finally, our mediation analysis should not be interpreted causally as it relies on diverse assumptions that cannot be fully satisfied using our study design.

417

In summary, this study highlights the serotype-specific modulation of infection risk based on 418 prior flavivirus exposure. The observation that individuals with prior ZIKV, DENV, or DENV-419 ZIKV infections were at increased risk of symptomatic dengue caused by multiple DENV 420 421 serotypes suggests that ADE potential is not limited to DENV2 but also extends DENV3 and DENV4. The findings presented here, in conjunction with other studies, suggest that the 422 introduction of a monovalent ZIKV vaccine that induces immunity similar to natural ZIKV 423 infection could have a negative effect on dengue outcome if introduced to DENV-naïve 424 populations. These findings advocate a more nuanced and integrative approach to vaccine 425 deployment strategies, considering the history of flavivirus infections and the level of flavivirus 426 immunity in the target population. Further, our results suggest that introducing ZIKV vaccines is 427 unlikely to broaden protective immunity in individuals with one prior DENV infection, and if 428 429 anything, may increase future dengue risk. Our findings also suggest that some individuals with two natural DENV infections remain at risk of DwWS/SD and may suggest that even some 430 individuals who are DENV immune before receiving dengue vaccines may remain at heightened 431 432 risk for disease. The possibility that vaccine-induced immunity could inadvertently elevate the risk of severe disease warrants an evidence-based approach to vaccination programs and longer-433 434 term follow-up times to evaluate protection against all DENV serotypes.

436

#### 437 MATERIALS AND METHODS

438 *Study design* 

This study aimed to assess how pre-existing ZIKV and DENV immunity impacts the risk of 439 symptomatic DENV1-4 and severe dengue disease, at a population level. To do this, we analyzed 440 serological data collected since 2004 from a continuous observational cohort study in Nicaragua, 441 adhering to the guidelines in the Strengthening the Reporting of Observational Studies in 442 Epidemiology checklist. This study did not involve any form of randomization or blinding 443 444 measures. Our analysis included all individuals, with results reported only for those with DENV and ZIKV infection histories that could be clearly determined. All relevant data available during 445 the manuscript preparation was included. The primary endpoint was the risk of symptomatic 446 DENV infection influenced by previous ZIKV or DENV immunity and the infecting DENV 447 serotype. Secondary endpoints were the impact of pre-existing antibody titers on dengue and 448 severe dengue risk, as well as antibody magnitude and long-term kinetics following exposure to 449 one or multiple flaviviruses. 450

451

#### 452 *Ethics statement*

The human subjects protocol of the Pediatric Dengue Cohort Study was reviewed and approved by the Institutional Review Boards of the University of California, Berkeley (2010-09-2245), the University of Michigan (HUM00091606), and the Nicaraguan Ministry of Health (CIRE-09/03/07-008). Parents or legal guardians of all subjects provided written informed consent, and participants aged 6 years of age and older provided assent.

#### 459 The Pediatric Dengue Cohort Study

The Pediatric Dengue Cohort Study is an ongoing prospective study that began in 2004 and is conducted at the Sócrates Flores Vivas Health Center (HCSFV), based in District 2 of Managua, Nicaragua (*46*). This district is adjacent to Lake Managua and consists of neighborhoods ranging from low to middle socioeconomic status (SES). The HCSFV serves approximately 62,000 residents across 18 neighborhoods within District 2 (*47*). The illiteracy rate in this area is approximately 7%, and over 90% of the households have access to running water and a sewage system. The streets are largely paved, and all residents have access to electricity (*48*).

467

The study tracks approximately 4,000 active participants yearly and has followed 9,800 children 468 since its inception. To maintain the original age distribution of the cohort, ~300 two-year-olds, 469 along with some children aged 3-11 years, are enrolled in the study each year. The age limit of 470 the study was increased to 15, 16, and 17 years in 2018, 2019, and 2022, respectively. 471 Participants are provided free medical care 24 hours per day, 365 days per year, through study 472 physicians at the HCSFV. If a child requires hospitalization, they are transferred by study staff to 473 the study hospital, the National Pediatric Reference Hospital (Hospital Infantil Manuel de Jesús 474 475 Rivera). Children presenting with fever and since July 2016, rash, are screened for signs and symptoms of dengue, Zika, and chikungunya. Symptomatic infections are captured through 476 passive surveillance, enhanced with periodic home visits. Acute (0-5 days post symptoms onset) 477 478 and convalescent samples (14-21 days) are collected for each suspected case to confirm infection 479 (35). Every year in March-April (previously in July before 2011), healthy blood samples are provided by all participants to evaluate inapparent arboviral infections (35). 480

#### 482 *Case definitions*

Upon medical examination, children are categorized into A, B, C, or D cases, as follows: A: 483 those meeting the 1997 or 2009 World Health Organization (WHO) criteria for dengue; B: those 484 with undifferentiated fever of undefined origin; C: those with an acute febrile illness identified as 485 a disease other than dengue, chikungunya, or Zika; D: those with other conditions (including 486 rash) that do not include a fever. A range of clinical and laboratory information is collected for 487 each participant, covering 189 different variables (35), including vital signs, temperature, 488 musculoskeletal pain, respiratory symptoms, gastrointestinal symptoms, indicators of 489 490 dehydration, rashes, and other skin anomalies. Since 2004, all cases falling into categories A and B are tested for acute DENV infection and, starting in 2014, also for chikungunya virus 491 (CHIKV). As of 2016, all cases meeting the definitions of A, B, or D (rash without fever) are 492 tested for acute DENV, CHIKV, and ZIKV infection. 493

494

Detection of cases: Acute samples are examined using the ZCD multiplex real-time reverse 495 transcriptase PCR (rRT-PCR) assay for DENV, ZIKV, and CHIKV (49); prior to the 496 introduction of ZIKV into the cohort, other RT-PCR methods were used (50-52). DENV-positive 497 samples are further analyzed by rRT-PCR to determine the infecting DENV serotype, and a 498 subset undergo virus isolation in C6/36 cells (50, 53). Paired acute-phase (days 1-5) and 499 convalescent-phase (days 14-21) samples are evaluated for seroconversion of IgM antibodies, an 500 501 indicator of a recent infection, using separate in-house DENV and ZIKV IgM capture (MAC)-ELISAs (54, 55). DENV inhibition ELISA (iELISA) and ZIKV iELISA assays are used to 502 measure total anti-DENV and -ZIKV antibodies, respectively, and to detect seroconversion or a 503 504 4-fold or greater increase in antibodies (12, 54). For arbovirus cases from 2016-2017, we also

used a computer algorithm to help identify Zika cases from dengue cases based on the results of
 the aforementioned antibody tests (*56*).

507

**Detection of inapparent infections**: To detect inapparent DENV infections, before 2016, we 508 identified an inapparent DENV infection if a seroconversion or a >4-fold increase in antibody 509 titer was recorded between annual samples as measured by DENV iELISA, provided no 510 observed febrile episode was identified as a dengue case (12). After the 2016 Zika epidemic, we 511 defined inapparent DENV infections as seroconversion or a  $\geq$ 4-fold rise in DENV iELISA titer 512 without seroconversion by ZIKV NS1 BOB ELISA, seroconversion or a >4-fold rise by ZIKV 513 iELISA, or an observed dengue, Zika, or flavivirus case in that year (54). Inapparent flavivirus 514 (DENV or ZIKV without ascertainment) infections were defined by seroconversion or a >4-fold 515 rise by both DENV iELISA and ZIKV iELISA, no seroconversion by ZIKV NS1 BOB ELISA, 516 and no documented dengue, Zika, or flavivirus case in that year. Seroconversion by ZIKV NS1 517 BOB ELISA and/or seroconversion or >4-fold rise by ZIKV iELISA was used to detect 518 inapparent ZIKV infections. 519

520

#### 521 Infection histories

The study participants were grouped into categories based on their DENV and/or ZIKV infection history. When a child experienced another infection, they were moved to the group that reflected their new infection status. We note that none of the groups with ZIKV existed before the major Zika epidemic in 2016. The different groups included children who: were free from DENV (from 2004-2015) or ZIKV (from 2016-2023) immunity at the start of the study and did not experience a DENV, ZIKV, or flavivirus infection during the study period (**flavivirus-naïve**); entered the

study with DENV immunity, determined using the DENV iELISA (titer  $\geq 1:10$ ) and with no 528 antibody titers as measured in other assays or with low ZIKV titers and no subsequent detected 529 infection (DENV-immune); were initially free from flaviviruses but were observed to have 530 experienced precisely one DENV infection (DENV); were initially free from flaviviruses but 531 who experienced exactly two documented DENV infections (DENV-DENV). Since 2020, ZIKV 532 533 titers were disregarded for new enrollees, given that most new enrollees did not experience the ZIKV epidemic, given their age, and there is no evidence that ZIKV has circulated after 2017. 534 Other groups included children who: either entered the study without flavivirus immunity and 535 536 experienced more than two documented DENV infections or who entered the study with flavivirus immunity and had one or more observed DENV infection (2+DENV); experienced 537 only one prior ZIKV infection (ZIKV) - these children either entered the study without 538 flavivirus immunity and had one observed ZIKV infection or a flavivirus infection (see 539 definition above; based on the epidemiology at the time, these are most likely ZIKV infections), 540 or positive for ZIKV but with low DENV titers. The **DENV-ZIKV** group included children who 541 experienced one DENV infection followed by one ZIKV infection; the 2+DENV-ZIKV group 542 included children with two or more prior DENV infections followed by one ZIKV infection; and 543 the ZIKV-DENV group comprised children with a primary ZIKV infection followed by one 544 DENV infection. The ZIKV-DENV group did not exist prior to the DENV2 epidemic in 2019. 545 Other infection histories included children who had a ZIKV-DENV infection history who 546 subsequently experienced another DENV infection (**ZIKV-DENV-DENV**); this group (N = 15) 547 experienced no subsequent DENV infections and was not included in our analyses of infection 548 histories, but they were included in the titer analyses. The DENV-ZIKV-2+DENV group 549 550 consisted of participants who initially had a DENV-ZIKV-DENV infection history and later

551 experienced another DENV infection. This group (N = 3) experienced no subsequent DENV infections and was not included in our analyses of infection histories, but they were included in 552 the titer analyses. Finally, the 2+DENV-ZIKV-DENV group consisted of participants who 553 initially were in the 2+DENV group and later had one ZIKV and other DENV infection. Again, 554 this group (N = 11) had no further infections and was not included in our analyses of infection 555 histories but was included in the titer analyses. Some children with ZIKV infections in 2016-556 2017 were observed to have increasing titers in DENV and ZIKV serological assays for multiple 557 years. These infections were not considered actual infections and were therefore excluded when 558 559 defining infection histories.

560

#### 561 *Severity classification*

Dengue cases in the study were classified according to the World Health Organization's (WHO) 562 guidelines from 1997 and 2009. According to the 1997 WHO case classification, Dengue Fever 563 (DF) was defined as a febrile case with at least two of the following symptoms: headache, 564 arthralgia, retro-orbital pain, rash, myalgia, hemorrhagic manifestations, and leukopenia. Dengue 565 Hemorrhagic Fever (DHF) was defined as a laboratory-confirmed dengue case presenting with: 566 567 1) fever or a history of fever; 2) hemorrhagic manifestations; 3) thrombocytopenia ( $\leq 100,000$ platelets/ml); and 4) signs of plasma leakage. The criteria for plasma leakage included age and 568 sex-specific elevated hematocrit levels,  $\geq 20\%$  hemoconcentration, pleural effusion, ascites, 569 edema, hypoproteinemia, hypoalbuminemia, or other evidence of plasma leak. Dengue Shock 570 Syndrome (**DSS**) is a DHF case with signs of circulatory failure, including 1) hypotension for the 571 patient's age or a narrow pulse pressure (<20 mm Hg), and 2) clinical signs of shock such as a 572 573 rapid, weak pulse, cold and clammy skin, or poor capillary refill.

574

575	According to the 2009 WHO case classification, Dengue with Warning Signs (DwWS) was used
576	when a laboratory-confirmed case presented with symptoms such as abdominal pain, persistent
577	vomiting, fluid accumulation, lethargy, mucosal bleeding, liver enlargement, or a rise in
578	hematocrit concurrent with a decrease in platelet count. Severe Dengue (SD) indicated
579	laboratory-confirmed cases with severe bleeding, significant plasma leakage leading to shock,
580	fluid accumulation resulting in respiratory distress, or organ failure. Organ involvement was
581	signified by liver ALT or AST levels of $\geq$ 1,000, impaired consciousness, or heart or other organ
582	failures.
583	
584	
585	Inclusion criteria for cases in the 2022 epidemic cases
586	Between March 19, 2022, and July 2, 2023, we documented 384 dengue cases. Notably, 15 of
587	these cases were identified based on DENV serology, but they also exhibited cross-reactivity
588	with ZIKV serology. Because ZIKV has not been detected since its initial introduction in the
589	region in 2016, these cases were classified as DENV cases in the present study. We excluded 10

cases that had a second-laboratory-confirmed DENV infection in the same epidemic, including 8 where both infections were confirmed by RT-PCR, and 2 where one of the infections was confirmed by DENV serology. Our analysis ultimately utilized 374 total cases, including 39 identified through DENV serology.

594

595 *Statistical analyses* 

All statistical and epidemiological analyses were conducted using R (R Foundation for Statistical

597 Computing, version 4.5.0) and used lme4, segmented, and mediation packages (57-60). Logbinomial and log-poisson generalized linear regression models (GLMs) were used to estimate the 598 risk of any dengue case given infection history. Log-poisson GLMs were used when log-599 binomial models would not converge due to rare disease outcomes; that is, in instances where we 600 had low numbers of dengue cases. Models were adjusted for age, sex, and time since last 601 602 infection. All analyses were also performed separately for each infecting DENV serotype. We were unable to analyze DENV serotype in analyses of DENV severity due to sample size 603 limitations. We calculated 95% confidence intervals (CIs) of the predicted values based on the 604 605 standard errors (SE), assuming a normal distribution (predicted mean plus or minus +1.96multiplied by the SE). GLMs were used for all 2022-2023 epidemic analyses since each 606 participant contributed only one year to the data. 607

For analyses using all 19 years of cohort data, generalized linear mixed models (GLMMs) were 608 used to incorporate random effects, allowing us to account for repeated measurements by 609 clustering at the individual level (longitudinal data analysis). We performed two main analyses: 610 one that studied the effect of infection histories on DENV outcomes, and one that categorized 611 participants as flavivirus-naïve versus those exposed to any number of DENV or ZIKV 612 infections (flavi-immune). Additionally, we adjusted for age, sex, time since last infection, and 613 cohort epidemic year. Neighborhood seroprevalence was also included as a proxy for exposure in 614 sensitivity analyses. Log-binomial and log-poisson GLMMs were used to model the relationship 615 616 between pre-existing DENV iELISA titers and disease outcome. These models were also adjusted for age, sex, time since the last infection and cohort epidemic year. 617

618

619 Mediation analysis was used to differentiate the direct versus indirect effect of antibody titers in

explaining the relationship between infection history and disease presentation for the 2022-2023 620 epidemic. Using logistic regression models, adjusting for age, sex, and year, we first regressed 621 the relationship between infection history and DENV iELISA titers and then we modeled the 622 likelihood of being a DENV case as a function of infection history and DENV iELISA titers. We 623 used non-parametric bootstrapping and bias-corrected, accelerated confidence intervals 624 employing 1,000 simulations. The indirect effects were calculated as the expected difference in 625 the potential outcomes if DENV iELISA titers were within a specific range versus outside of that 626 range. We performed separate analyses comparing titers of 10-320 vs. higher or lower and >320627 628 vs. <320. We performed pairwise comparisons of flavivirus-naïve vs non-flavivirus-naïve categories (DENV immune, DENV, ZIKV, DENV-DENV, DENV-ZIKV, ZIKV-DENV, 629 2+DENV, 2+DENV-ZIKV) resulting in eight comparisons or contrasts. The proportion of 630 mediation was determined by dividing the indirect effect by the total effect. When a mediation 631 model was inconsistent, meaning that the direct and indirect effects were in opposite signs, the 632 absolute value of them were used to calculate the mediation contribution proportion (61). 633

634

We measured antibody dynamics by infection history group using Gaussian generalized additive 635 mixed models (GAMMs) that included random effects for both the intercept and slope, as each 636 individual had a different starting titer magnitude and titer kinetics. Antibody dynamics analyses 637 were adjusted for age and sex. For computational efficiency purposes, in order to account for the 638 639 individual variability, all continuous covariates were discretized, including time since last infection (but allowing time since last infection to be smooth) and variance parameters were 640 estimated using a fast restricted maximun likelihood (REML) function (62). We used these 641 642 models to identify relevant inflection points in the antibody kinetics for further analyses related

643	to intercepts and slopes within each infection history group. Multiphasic linear models were then
644	used to model the various phases of antibody decay or rise while estimating antibody half-lives.
645	Half-lives were calculated by dividing log(2) titers by the slope. A positive half-life indicated
646	that antibody titers waned, whereas a negative-half-life represented increasing antibody titers.
647	

#### 648 **References and Notes**

- S. Leta, T. J. Beyene, E. M. De Clercq, K. Amenu, M. U. G. Kraemer, C. W. Revie, 1. 649 Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes 650 albopictus. Int. J. Infect. Dis. 67, 25-35 (2018). 651 L. Cattarino, I. Rodriguez-Barraquer, N. Imai, D. A. T. Cummings, N. M. Ferguson, 2. 652 653 Mapping global variation in dengue transmission intensity. Sci. Transl. Med. 12, eaax4144 (2020). 654 3. N. R. Faria, J. Quick, I. M. Claro, J. Theze, J. G. de Jesus, M. Giovanetti, M. U. G. 655 Kraemer, S. C. Hill, A. Black, A. C. da Costa, L. C. Franco, S. P. Silva, C. H. Wu, J. 656 Raghwani, S. Cauchemez, L. du Plessis, M. P. Verotti, W. K. de Oliveira, E. H. Carmo, 657 G. E. Coelho, Acfs Santelli, L. C. Vinhal, C. M. Henriques, J. T. Simpson, M. Loose, K. 658 G. Andersen, N. D. Grubaugh, S. Somasekar, C. Y. Chiu, J. E. Munoz-Medina, C. R. 659 Gonzalez-Bonilla, C. F. Arias, L. L. Lewis-Ximenez, S. A. Baylis, A. O. Chieppe, S. F. 660 Aguiar, C. A. Fernandes, P. S. Lemos, B. L. S. Nascimento, H. A. O. Monteiro, I. C. 661 Siqueira, M. G. de Queiroz, T. R. de Souza, J. F. Bezerra, M. R. Lemos, G. F. Pereira, D. 662 Loudal, L. C. Moura, R. Dhalia, R. F. Franca, T. Magalhaes, E. T. Marques, Jr., T. 663 664 Jaenisch, G. L. Wallau, M. C. de Lima, V. Nascimento, E. M. de Cerqueira, M. M. de Lima, D. L. Mascarenhas, J. P. M. Neto, A. S. Levin, T. R. Tozetto-Mendoza, S. N. 665 Fonseca, M. C. Mendes-Correa, F. P. Milagres, A. Segurado, E. C. Holmes, A. Rambaut, 666 667 T. Bedford, M. R. T. Nunes, E. C. Sabino, L. C. J. Alcantara, N. J. Loman, O. G. Pybus, Establishment and cryptic transmission of Zika virus in Brazil and the Americas. Nature 668 **546**, 406-410 (2017). 669
- 4. A. E. Ngono, S. Shresta, Immune Response to Dengue and Zika. *Annu. Rev. Immunol.*

671	<b>36</b> , 279-308	(2018).
-----	---------------------	---------

- 5. L. C. Katzelnick, S. Bos, E. Harris, Protective and enhancing interactions among dengue
  viruses 1-4 and Zika virus. *Curr. Opin. Virol.* 43, 59-70 (2020).
- 674 6. E. N. Gallichotte, R. S. Baric, A. M. de Silva, The Molecular Specificity of the Human
- Antibody Response to Dengue Virus Infections. Adv. Exp. Med. Biol. 1062, 63-76
- 676 (2018).
- L. C. Katzelnick, M. Montoya, L. Gresh, A. Balmaseda, E. Harris, Neutralizing antibody
  titers against dengue virus correlate with protection from symptomatic infection in a
  longitudinal cohort. *Proc. Natl. Acad. Sci. U S A* **113**, 728-733 (2016).
- 680 8. S. Bos, A. L. Graber, J. A. Cardona-Ospina, E. M. Duarte, J. V. Zambrana, J. A. Ruiz
- 681 Salinas, R. Mercado-Hernandez, T. Singh, L. C. Katzelnick, A. de Silva, G. Kuan, A.
- Balmaseda, E. Harris, The association of neutralizing antibodies with protection against

683 symptomatic dengue virus infection varies by serotype, prior infection history, and assay

684 condition. *medRxiv*, Preprint at: https://doi.org/10.1101/2023.06.20.23291522 (2023).

- 685 9. D. Buddhari, J. Aldstadt, T. P. Endy, A. Srikiatkhachorn, B. Thaisomboonsuk, C.
- 686 Klungthong, A. Nisalak, B. Khuntirat, R. G. Jarman, S. Fernandez, S. J. Thomas, T. W.
- 687 Scott, A. L. Rothman, I. K. Yoon, Dengue virus neutralizing antibody levels associated
- with protection from infection in thai cluster studies. *PLoS Negl. Trop. Dis.* **8**, e3230
- 689 (2014).
- 690 10. A. Nisalak, H. E. Clapham, S. Kalayanarooj, C. Klungthong, B. Thaisomboonsuk, S.
- 691 Fernandez, J. Reiser, A. Srikiatkhachorn, L. R. Macareo, J. T. Lessler, D. A. Cummings,
- 692 I. K. Yoon, Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in
- 693 Bangkok, Thailand, 1973-2012. Am. J. Trop. Med. Hyg. 94, 1342-1347 (2016).

694	11.	N. Sangkawibha, S. Rojanasuphot, S. Ahandrik, S. Viriyapongse, S. Jatanasen, V. Salitul,
695		B. Phanthumachinda, S. B. Halstead, Risk factors in dengue shock syndrome: a
696		prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J.
697		<i>Epidemiol.</i> <b>120</b> , 653-669 (1984).
698	12.	L. C. Katzelnick, L. Gresh, M. E. Halloran, J. C. Mercado, G. Kuan, A. Gordon, A.
699		Balmaseda, E. Harris, Antibody-dependent enhancement of severe dengue disease in
700		humans. Science <b>358</b> , 929-932 (2017).
701	13.	H. Salje, D. A. T. Cummings, I. Rodriguez-Barraquer, L. C. Katzelnick, J. Lessler, C.
702		Klungthong, B. Thaisomboonsuk, A. Nisalak, A. Weg, D. Ellison, L. Macareo, I. K.
703		Yoon, R. Jarman, S. Thomas, A. L. Rothman, T. Endy, S. Cauchemez, Reconstruction of
704		antibody dynamics and infection histories to evaluate dengue risk. Nature 557, 719-723
705		(2018).
706	14.	S. B. Halstead, S. Nimmannitya, S. N. Cohen, Observations related to pathogenesis of
707		dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and
708		virus recovered. Yale. J. Biol. Med. 42, 311-328 (1970).
709	15.	S. B. Halstead, E. J. O'Rourke, Dengue viruses and mononuclear phagocytes. I. Infection
710		enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201-217 (1977).
711	16.	M. G. Guzman, M. Alvarez, S. B. Halstead, Secondary infection as a risk factor for
712		dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of
713		antibody-dependent enhancement of infection. Arch. Virol. 158, 1445-1459 (2013).
714	17.	C. F. Estofolete, A. F. Versiani, F. S. Dourado, Bhga Milhim, C. C. Pacca, G. C. D. Silva,
715		N. Zini, B. F. D. Santos, F. A. Gandolfi, N. F. B. Mistrao, P. H. C. Garcia, R. S. Rocha,
716		L. Gehrke, I. Bosch, R. E. Marques, M. M. Teixeira, F. G. da Fonseca, N. Vasilakis, M.

717	L. Nogueira, Influence of previous Zika virus infection on acute dengue episode. <i>PLoS</i>
718	Negl. Trop. Dis. 17, e0011710 (2023).

- 18. Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D, Ampie O,
- 720 Elizondo D, Miranda T, Bustos Carillo F, Mercado JC, Latta K, Schiller A, Segovia-
- 721 Chumbez B, Ojeda S, Sanchez N, Plazaola M, Coloma J, Halloran ME, Premkumar L,
- 722 Gordon A, Narvaez F, de Silva AM, Kuan G, Balmaseda A, Harris E, Zika virus
- infection enhances future risk of severe dengue disease. *Science (New York, N.Y.)* **369**,

724 1123-1128 (2020).

- 19. M. E. Breitbach, C. M. Newman, D. M. Dudley, L. M. Stewart, M. T. Aliota, M. R.
- Koenig, P. M. Shepherd, K. Yamamoto, C. M. Crooks, G. Young, M. R. Semler, A. M.
- Weiler, G. L. Barry, H. Heimsath, E. L. Mohr, J. Eichkoff, W. Newton, E. Peterson, N.
- 728 Schultz-Darken, S. R. Permar, H. Dean, S. Capuano, 3rd, J. E. Osorio, T. C. Friedrich, D.
- H. O'Connor, Primary infection with dengue or Zika virus does not affect the severity of
- heterologous secondary infection in macaques. *PLoS Pathog.* **15**, e1007766 (2019).
- 731 20. J. George, W. G. Valiant, M. J. Mattapallil, M. Walker, Y. S. Huang, D. L.
- Vanlandingham, J. Misamore, J. Greenhouse, D. E. Weiss, D. Verthelyi, S. Higgs, H.
- Andersen, M. G. Lewis, J. J. Mattapallil, Prior Exposure to Zika Virus Significantly
- Enhances Peak Dengue-2 Viremia in Rhesus Macaques. *Sci Rep* **7**, 10498 (2017).
- 735 21. M. G. Guzman, G. Kouri, L. Valdes, J. Bravo, M. Alvarez, S. Vazques, I. Delgado, S. B.
- Halstead, Epidemiologic studies on Dengue in Santiago de Cuba, 1997. *Am. J. Epidemiol.*152, 793-799 (2000).
- 738 22. I. Y. Amaya-Larios, R. A. Martinez-Vega, F. A. Diaz-Quijano, E. Sarti, E. Puentes-
- Rosas, L. Chihu, J. Ramos-Castaneda, Risk of dengue virus infection according to

740		serostatus in individuals from dengue endemic areas of Mexico. Sci Rep 10, 19017
741		(2020).
742	23.	S. Henein, J. Swanstrom, A. M. Byers, J. M. Moser, S. F. Shaik, M. Bonaparte, N.
743		Jackson, B. Guy, R. Baric, A. M. de Silva, Dissecting Antibodies Induced by a Chimeric
744		Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in
745		Naive and Dengue-Exposed Individuals. J. Infect. Dis. 215, 351-358 (2017).
746	24.	E. Harris, E. Videa, L. Perez, E. Sandoval, Y. Tellez, M. L. Perez, R. Cuadra, J. Rocha,
747		W. Idiaquez, R. E. Alonso, M. A. Delgado, L. A. Campo, F. Acevedo, A. Gonzalez, J. J.
748		Amador, A. Balmaseda, Clinical, epidemiologic, and virologic features of dengue in the
749		1998 epidemic in Nicaragua. Am. J. Trop. Med. Hyg. 63, 5-11 (2000).
750	25.	Z. Moodie, M. Juraska, Y. Huang, Y. Zhuang, Y. Fong, L. N. Carpp, S. G. Self, L.
751		Chambonneau, R. Small, N. Jackson, F. Noriega, P. B. Gilbert, Neutralizing Antibody
752		Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin
753		America. J. Infect. Dis. 217, 742-753 (2018).
754	26.	L. C. Katzelnick, C. Narvaez, S. Arguello, B. Lopez Mercado, D. Collado, O. Ampie, D.
755		Elizondo, T. Miranda, F. Bustos Carillo, J. C. Mercado, K. Latta, A. Schiller, B. Segovia-
756		Chumbez, S. Ojeda, N. Sanchez, M. Plazaola, J. Coloma, M. E. Halloran, L. Premkumar,
757		A. Gordon, F. Narvaez, A. M. de Silva, G. Kuan, A. Balmaseda, E. Harris, Zika virus
758		infection enhances future risk of severe dengue disease. Science 369, 1123-1128 (2020).
759	27.	S. Olkowski, B. M. Forshey, A. C. Morrison, C. Rocha, S. Vilcarromero, E. S. Halsey, T.
760		J. Kochel, T. W. Scott, S. T. Stoddard, Reduced risk of disease during postsecondary
761		dengue virus infections. J. Infect. Dis. 208, 1026-1033 (2013).
762	28.	L. C. Katzelnick, J. V. Zambrana, D. Elizondo, D. Collado, N. Garcia, S. Arguello, J. C.

763		Mercado, T. Miranda, O. Ampie, B. L. Mercado, C. Narvaez, L. Gresh, R. A. Binder, S.
764		Ojeda, N. Sanchez, M. Plazaola, K. Latta, A. Schiller, J. Coloma, F. B. Carrillo, F.
765		Narvaez, M. E. Halloran, A. Gordon, G. Kuan, A. Balmaseda, E. Harris, Dengue and
766		Zika virus infections in children elicit cross-reactive protective and enhancing antibodies
767		that persist long term. Sci. Transl. Med. 13, eabg9478 (2021).
768	29.	Pérez-Guzmán EX, Pantoja P, Serrano-Collazo C, Hassert MA, Ortiz-Rosa A, Rodríguez
769		IV, Giavedoni L, Hodara V, Parodi L, Cruz L, Arana T, White LJ, Martínez MI,
770		Weiskopf D, Brien JD, de Silva A, Pinto AK, Sariol CA, Time elapsed between Zika and
771		dengue virus infections affects antibody and T cell responses. Nat. comm. 10, (2019).
772	30.	N. Marzan-Rivera, C. Serrano-Collazo, L. Cruz, P. Pantoja, A. Ortiz-Rosa, T. Arana, M.
773		I. Martinez, A. G. Burgos, C. Roman, L. B. Mendez, E. Geerling, A. K. Pinto, J. D.
774		Brien, C. A. Sariol, Infection order outweighs the role of CD4(+) T cells in tertiary
775		flavivirus exposure. <i>iScience</i> <b>25</b> , 104764 (2022).
776	31.	B. M. Valencia, P. C. Sigera, P. Weeratunga, N. Tedla, D. Fernando, S. Rajapakse, A. R.
777		Lloyd, C. Rodrigo, Effect of prior Zika and dengue virus exposure on the severity of a
778		subsequent dengue infection in adults. Sci. Rep. 12, 17225 (2022).
779	32.	P. Bhoomiboonchoo, A. Nisalak, N. Chansatiporn, I. K. Yoon, S. Kalayanarooj, M.
780		Thipayamongkolgul, T. Endy, A. L. Rothman, S. Green, A. Srikiatkhachorn, D.
781		Buddhari, M. P. Mammen, R. V. Gibbons, Sequential dengue virus infections detected in
782		active and passive surveillance programs in Thailand, 1994-2010. BMC Public Health 15,
783		250 (2015).
784	33.	R. V. Gibbons, S. Kalanarooj, R. G. Jarman, A. Nisalak, D. W. Vaughn, T. P. Endy, M.

P. Mammen, Jr., A. Srikiatkhachorn, Analysis of repeat hospital admissions for dengue to

786		estimate the frequency of third or fourth dengue infections resulting in admissions and
787		dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg. 77, 910-913
788		(2007).
789	34.	M. Montoya, L. Gresh, J. C. Mercado, K. L. Williams, M. J. Vargas, G. Gutierrez, G.
790		Kuan, A. Gordon, A. Balmaseda, E. Harris, Symptomatic versus inapparent outcome in
791		repeat dengue virus infections is influenced by the time interval between infections and
792		study year. PLoS Negl. Trop. Dis. 7, e2357 (2013).
793	35.	A. Gordon, G. Kuan, J. C. Mercado, L. Gresh, W. Aviles, A. Balmaseda, E. Harris, The
794		Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic
795		dengue virus infections, 2004-2010. PLoS Negl. Trop. Dis. 7, e2462 (2013).
796	36.	T. K. Tsang, S. L. Ghebremariam, L. Gresh, A. Gordon, M. E. Halloran, L. C.
797		Katzelnick, D. P. Rojas, G. Kuan, A. Balmaseda, J. Sugimoto, E. Harris, I. M. Longini,
798		Jr., Y. Yang, Effects of infection history on dengue virus infection and pathogenicity. Nat
799		<i>Commun</i> <b>10</b> , 1246 (2019).
800	37.	K. M. Soo, B. Khalid, S. M. Ching, H. Y. Chee, Meta-Analysis of Dengue Severity
801		during Infection by Different Dengue Virus Serotypes in Primary and Secondary
802		Infections. PLoS One 11, e0154760 (2016).
803	38.	R. Raut, K. S. Corbett, R. N. Tennekoon, S. Premawansa, A. Wijewickrama, G.
804		Premawansa, P. Mieczkowski, C. Ruckert, G. D. Ebel, A. D. De Silva, A. M. de Silva,
805		Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized
806		by human antibodies. Proc. Natl. Acad. Sci. U S A 116, 227-232 (2019).
807	39.	K. A. Dowd, C. R. DeMaso, T. C. Pierson, Genotypic Differences in Dengue Virus
808		Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus

809 Breathing. *mBio* **6**, e01559-01515 (2015).

- 40. H. Salje, M. T. Alera, M. N. Chua, T. Hunsawong, D. Ellison, A. Srikiatkhachorn, R. G.
- Jarman, G. D. Gromowski, I. Rodriguez-Barraquer, S. Cauchemez, D. A. T. Cummings,
- L. Macareo, I. K. Yoon, S. Fernandez, A. L. Rothman, Evaluation of the extended
- efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
- 814 Nat. Med. 27, 1395-1400 (2021).
- 41. L. Lopez, R. E. Paul, V. M. Cao-Lormeau, X. Rodo, Considering waning immunity to
  better explain dengue dynamics. *Epidemics* 41, 100630 (2022).
- 42. K. B. Anderson, R. V. Gibbons, D. A. Cummings, A. Nisalak, S. Green, D. H. Libraty, R.
- G. Jarman, A. Srikiatkhachorn, M. P. Mammen, B. Darunee, I. K. Yoon, T. P. Endy, A
- shorter time interval between first and second dengue infections is associated with
- protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209,
  360-368 (2014).
- 43. O. Brathwaite Dick, J. L. San Martin, R. H. Montoya, J. del Diego, B. Zambrano, G. H.
  Dayan, The history of dengue outbreaks in the Americas. *Am. J. Trop. Med. Hyg.* 87,
  584-593 (2012).
- 44. H. C. Metsky, C. B. Matranga, S. Wohl, S. F. Schaffner, C. A. Freije, S. M. Winnicki, K.
- West, J. Qu, M. L. Baniecki, A. Gladden-Young, A. E. Lin, C. H. Tomkins-Tinch, S. H.
- Ye, D. J. Park, C. Y. Luo, K. G. Barnes, R. R. Shah, B. Chak, G. Barbosa-Lima, E.
- Delatorre, Y. R. Vieira, L. M. Paul, A. L. Tan, C. M. Barcellona, M. C. Porcelli, C.
- Vasquez, A. C. Cannons, M. R. Cone, K. N. Hogan, E. W. Kopp, J. J. Anzinger, K. F.
- Garcia, L. A. Parham, R. M. G. Ramirez, M. C. M. Montoya, D. P. Rojas, C. M. Brown,
- 831 S. Hennigan, B. Sabina, S. Scotland, K. Gangavarapu, N. D. Grubaugh, G. Oliveira, R.

832		Robles-Sikisaka, A. Rambaut, L. Gehrke, S. Smole, M. E. Halloran, L. Villar, S. Mattar,
833		I. Lorenzana, J. Cerbino-Neto, C. Valim, W. Degrave, P. T. Bozza, A. Gnirke, K. G.
834		Andersen, S. Isern, S. F. Michael, F. A. Bozza, T. M. L. Souza, I. Bosch, N. L. Yozwiak,
835		B. L. MacInnis, P. C. Sabeti, Zika virus evolution and spread in the Americas. Nature
836		<b>546</b> , 411-415 (2017).
837	45.	Q. Zhang, K. Sun, M. Chinazzi, Y. Piontti A. Pastore, N. E. Dean, D. P. Rojas, S. Merler,
838		D. Mistry, P. Poletti, L. Rossi, M. Bray, M. E. Halloran, I. M. Longini, Jr., A.
839		Vespignani, Spread of Zika virus in the Americas. Proc. Natl. Acad. Sci. USA 114,
840		E4334-E4343 (2017).
841	46.	G. Kuan, A. Gordon, W. Aviles, O. Ortega, S. N. Hammond, D. Elizondo, A. Nunez, J.
842		Coloma, A. Balmaseda, E. Harris, The Nicaraguan pediatric dengue cohort study: study
843		design, methods, use of information technology, and extension to other infectious
844		diseases. Am. J. Epidemiol. 170, 120-129 (2009).
845	47.	A. Gordon, G. Kuan, W. Aviles, N. Sanchez, S. Ojeda, B. Lopez, L. Gresh, A.
846		Balmaseda, E. Harris, The Nicaraguan pediatric influenza cohort study: design, methods,
847		use of technology, and compliance. BMC Infect. Dis. 15, 504 (2015).
848	48.	J. V. Zambrana, F. Bustos Carrillo, R. Burger-Calderon, D. Collado, N. Sanchez, S.
849		Ojeda, J. Carey Monterrey, M. Plazaola, B. Lopez, S. Arguello, D. Elizondo, W. Aviles,
850		J. Coloma, G. Kuan, A. Balmaseda, A. Gordon, E. Harris, Seroprevalence, risk factor,
851		and spatial analyses of Zika virus infection after the 2016 epidemic in Managua,
852		Nicaragua. Proc. Natl. Acad. Sci. U S A 115, 9294-9299 (2018).
853	49.	J. J. Waggoner, L. Gresh, A. Mohamed-Hadley, G. Ballesteros, M. J. Davila, Y. Tellez,
854		M. K. Sahoo, A. Balmaseda, E. Harris, B. A. Pinsky, Single-Reaction Multiplex Reverse

855	Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. <i>Emerg.</i>
856	Infect. Dis. 22, 1295-1297 (2016).

- 50. A. Balmaseda, E. Sandoval, L. Perez, C. M. Gutierrez, E. Harris, Application of
- molecular typing techniques in the 1998 dengue epidemic in Nicaragua. *Am. J. Trop.*
- 859 *Med. Hyg.* **61**, 893-897 (1999).
- 860 51. R. S. Lanciotti, C. H. Calisher, D. J. Gubler, G. J. Chang, A. V. Vorndam, Rapid
- detection and typing of dengue viruses from clinical samples by using reverse
- transcriptase-polymerase chain reaction. *J Clin Microbiol* **30**, 545-551 (1992).
- 52. J. J. Waggoner, G. Ballesteros, L. Gresh, A. Mohamed-Hadley, Y. Tellez, M. K. Sahoo,
- J. Abeynayake, A. Balmaseda, E. Harris, B. A. Pinsky, Clinical evaluation of a single-

reaction real-time RT-PCR for pan-dengue and chikungunya virus detection. J. Clin.

866 *Virol.* **78**, 57-61 (2016).

53. J. J. Waggoner, J. Abeynayake, M. K. Sahoo, L. Gresh, Y. Tellez, K. Gonzalez, G.

Ballesteros, A. M. Pierro, P. Gaibani, F. P. Guo, V. Sambri, A. Balmaseda, K.

- Karunaratne, E. Harris, B. A. Pinsky, Single-reaction, multiplex, real-time rt-PCR for the
- detection, quantitation, and serotyping of dengue viruses. *PLoS Negl. Trop. Dis.* 7, e2116
  (2013).
- 54. A. Balmaseda, J. V. Zambrana, D. Collado, N. Garcia, S. Saborio, D. Elizondo, J. C.
- 873 Mercado, K. Gonzalez, C. Cerpas, A. Nunez, D. Corti, J. J. Waggoner, G. Kuan, R.
- 874 Burger-Calderon, E. Harris, Comparison of Four Serological Methods and Two Reverse
- 875 Transcription-PCR Assays for Diagnosis and Surveillance of Zika Virus Infection. J.
- 876 *Clin. Microbiol.* **56**, 56(3):e01785-17 (2018).
- 55. A. Balmaseda, M. G. Guzman, S. Hammond, G. Robleto, C. Flores, Y. Tellez, E. Videa,

878		S. Saborio, L. Perez, E. Sandoval, Y. Rodriguez, E. Harris, Diagnosis of dengue virus
879		infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum
880		and saliva. Clin. Diagn. Lab. Immunol. 10, 317-322 (2003).
881	56.	A. Gordon, L. Gresh, S. Ojeda, L. C. Katzelnick, N. Sanchez, J. C. Mercado, G. Chowell,
882		B. Lopez, D. Elizondo, J. Coloma, R. Burger-Calderon, G. Kuan, A. Balmaseda, E.
883		Harris, Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua.
884		<i>PLoS Med.</i> <b>16</b> , e1002726 (2019).
885	57.	Dustin Tingley, Teppei Yamamoto, Kentaro Hirose, Luke Keele, Kosuke Imai,
886		mediation: R Package for Causal Mediation Analysis. J. of Stat. Soft. 59, (2014).
887	58.	R Core Team. R: A Language and Environment for Statistical Computing (2023).
888	59.	Vito M. R. Muggeo, Testing with a nuisance parameter present only under the
889		alternative: a score-based approach with application to segmented modelling. J. of Stat.
890		Comp. and Sim. 86, 3059-3067 (2016).
891	60.	Douglas Bates, Martin Mächler, Ben Bolker, Steve Walker, Fitting Linear Mixed-Effects
892		Models Using lme4. J. of Stat. Soft. 67, 1-48 (2015).
893	61.	D. Alwin, R. Hauser, The Decomposition of Effects in Path Analysis. American
894		Sociological Review, <b>40</b> , 37-47 (1975).
895	62.	Simon N. Wood, Yannig Goude, Simon Shaw, Generalized Additive Models for Large
896		Data Sets. Journal of the Royal Statistical Society Series C: Applied Statistics 64, 139-
897		155 (2015).
898		
899		

#### 901 Acknowledgments:

902	We thank the participants of	he Pediatric Dengue Co	ohort Study and their families. V	We are
-----	------------------------------	------------------------	-----------------------------------	--------

- grateful to both past and current team members of the study, based at the Sócrates Flores Vivas
- Health Center, the Laboratorio Nacional de Virología in the Centro Nacional de Diagnóstico y
- 905 Referencia, and the Sustainable Sciences Institute in Nicaragua for their commitment and
- 906 exceptional work.
- 907

#### 908 **Funding:**

- <sup>909</sup> This work was supported by National Institutes of Health grants P01AI106695 (EH),
- 910 U19AI118610 (EH) and R01AI099631 (AB), Pediatric Dengue Vaccine Initiative grant VE-1
- 911 (EH), the Bill and Melinda Gates Foundation FIRST grant (EH), and the Division of Intramural
- 912 Research of the National Institute of Allergy and Infectious Diseases (LCK).
- 913

#### 914 Author contributions:

- 915 Conceptualization: JVZ, CMH, RAA, SB, LCK, EH
- 916 Methodology: JVZ, CMH, RAA, LCK, EH
- 917 Investigation: SA, CN, KG, DC, TM, GK, AB
- 918 Visualization: JVZ, CMH, RAA
- 919 Funding acquisition: AB, LCK, EH
- 920 Project administration: GK, AG, AB, EH
- 921 Supervision: LCK, EH
- 922 Writing original draft: JVZ, CMH, RAA, LCK, EH
- 923 Writing review & editing: All authors.

924

#### 925 **Competing interests:**

926 EH's laboratory received research funds from Takeda Vaccines Inc. to test samples from vaccine

- 927 recipients. EH served on one-time advisory boards for Merck and Takeda. AG served on an RSV
- 928 vaccine scientific advisory board for Janssen.

929

#### 930 Data and materials availability:

All data pertinent to this study can be found within the paper or the Supplementary Materials.

and the associated code is available for reference on Zenodo. After securing approval from the

933 UC Berkeley Committee for the Protection of Human Subjects, individual data for figure

reproduction could be shared with external researchers. For data access arrangements, please

contact EH at eharris@berkeley.edu. Standard data and material transfer agreements govern all

materials and data used in this study.

937

#### 938 Supplementary materials

939 Fig. S1 to S3

940 Table S1 to S7

941

#### 943 FIGURE LEGENDS

944

945	Fig. 1.	Nicaragua	experienced	a large den	gue epidemic ir	n 2022-2023 w	vith co-circulation of
-----	---------	-----------	-------------	-------------	-----------------	---------------	------------------------

- 946 all four serotypes. Monthly dengue and Zika cases (A), the proportion of individuals with
- various infection histories (B), and DENV iELISA titer distribution (C) by epidemic year in the
- 948 Pediatric Dengue Cohort Study (2004-2022).

949

#### 950 Fig. 2. Prior infection history confers differential risk of symptomatic DENV1, DENV3 and

951 **DENV4 and overall disease and disease severity.** Log-binomial and log-Poisson generalized

linear models (GLMs) were used to estimate the risk of any dengue case, a case caused by

953 DENV1, DENV2, DENV3, or DENV4, and Dengue with Warning Signs/Severe Dengue

954 (DwWS/SD) by DENV and ZIKV infection history in (A) the 2022-2023 epidemic or (B) all

955 years of the cohort study (2004-2023).

956

#### 957 Fig. 3. History of prior flavivirus infection exacerbates risk of symptomatic DENV2 and

958 **DENV4 and overall disease and disease severity.** Linear mixed effects models were used to

estimate the risks of a symptomatic DENV infection (case) by any serotype or from and DENV1,

960 DENV2, DENV3, or DENV4 infection (A) and Dengue with Warning Signs/Severe Dengue

961 (DwWS/SD) and Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) (**B**) in the

prospective cohort study, 2004-2023 by immune status (naïve or flavivirus immune).

963

#### Fig. 4. Risks of dengue differ by pre-existing anti-DENV antibody titers and infecting

serotype. Linear mixed effects models were used to estimate the risk of any symptomatic DENV

<sup>966</sup> infection, as well as a symptomatic infection caused by DENV1-4 by pre-existing DENV

- 967 iELISA titer during (A) the 2022-2023 epidemic or (B) all years of the cohort study (2004-2023).
  968
- 969 Fig. 5. DENV iELISA titer is a mediator that helps explain the relationship between
- 970 infection history and disease outcome. A) Mediation path diagram and effects and contribution
- of DENV iELISA titers (between 10 and 320) on disease risk attributed to prior flavivirus
- 972 infection. B) Mediation path diagram and effects and contribution of DENV iELISA titers
- 973 (>320) on disease risk attributed to prior flavivirus infection.
- 974

```
975 Fig. 6. Primary DENV and ZIKV infections have distinct antibody dynamics as well as the
```

- 976 order of DENV or ZIKV infections. Antibody kinetics in the Pediatric Dengue Cohort Study,
- as measured using the DENV iELISA, are shown. Data are shown for 1 to up to 10 years for the
- 978 following infection histories: DENV-immune (A), primary DENV (B), primary ZIKV (C),
- 979 DENV-DENV (D), DENV-ZIKV (E), ZIKV-DENV (F), 2+DENV (G), and 2+DENV-ZIKV
- 980 (H) infections. Individual trajectories and group Generalized Additive Model fits (black line;
- 981 95% CIs, gray shading) are shown.

### Table. 1. Characteristics of participants in the Pediatric Dengue Cohort Study with documented infection histories in 2022-23.

984

	Total		DENV cases					
	Population							
Variable	N = 3,564 <sup>1</sup>	Overall, N	DENV1, N	DENV2,	DENV3, N	DENV4,	Dengue	p-value <sup>2</sup>
		= 374 <sup>1</sup>	= 139 <sup>1</sup>	$N = 9^{1}$	= 54 <sup>1</sup>	$N = 133^{1}$	serology,	
							$N = 39^{1}$	
Age	10.4 (4.0)	11.0 (3.6)	10.6 (3.8)	10.2 (4.7)	11.1 (3.7)	11.9 (3.3)	9.7 (3.3)	0.003
Sex								0.2
F	1,768 (50%)	193 (52%)	64 (46%)	4 (44%)	25 (46%)	78 (59%)	22 (56%)	
Μ	1,794 (50%)	179 (48%)	74 (54%)	5 (56%)	29 (54%)	54 (41%)	17 (44%)	
DHF/DSS	3 (<0.1%)	3 (0.8%)	1 (0.7%)	0 (0%)	2 (3.7%)	0 (0%)	0 (0%)	0.2
DwWS/SD	57 (1.6%)	57 (15%)	27 (19%)	1 (11%)	4 (7.4%)	23 (17%)	2 (5.1%)	0.076
Time since last	5.50 (3.00)	5.81	5.90	6.25	6.41	5.35	6.18	0.049
infection		(2.87)	(3.01)	(3.65)	(2.97)	(2.73)	(2.33)	
Geometric Mean	665 (1,985)	390	314	6 (11)	58 (198)	684	154 (563)	<0.001
Titer (iELISA)		(1,400)	(1,263)			(1,876)		
Infection history								
Naive	1,559 (46%)	123 (35%)	55 (43%)	4 (50%)	19 (37%)	24 (19%)	21 (62%)	
DENV-immune	113 (3.3%)	12 (3.4%)	3 (2.3%)	0 (0%)	4 (7.8%)	4 (3.1%)	1 (2.9%)	
DENV	299 (8.8%)	33 (9.5%)	11 (8.6%)	0 (0%)	1 (2.0%)	20 (16%)	1 (2.9%)	
ZIKV	742 (22%)	110 (32%)	37 (29%)	4 (50%)	21 (41%)	41 (32%)	7 (21%)	
DENV-DENV	63 (1.8%)	12 (3.4%)	7 (5.5%)	0 (0%)	1 (2.0%)	4 (3.1%)	0 (0%)	
DENV-ZIKV	174 (5.1%)	25 (7.2%)	6 (4.7%)	0 (0%)	0 (0%)	17 (13%)	2 (5.9%)	
ZIKV-DENV	334 (9.8%)	25 (7.2%)	7 (5.5%)	0 (0%)	4 (7.8%)	13 (10%)	1 (2.9%)	
2+DENV	56 (1.6%)	2 (0.6%)	1 (0.8%)	0 (0%)	0 (0%)	1 (0.8%)	0 (0%)	
2+DENV-ZIKV	43 (1.3%)	6 (1.7%)	1 (0.8%)	0 (0%)	1 (2.0%)	3 (2.4%)	1 (2.9%)	
DENV-ZIKV-	3 (<0.1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
2+DENV								
ZIKV-DENV- DENV	15 (0.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
2+DENV-ZIKV- DENV	11 (0.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	

<sup>1</sup>Mean (SD); n (%)

<sup>2</sup>Kruskal-Wallis rank sum test; Fisher's exact test



#### Risk of dengue disease by prior DENV and ZIKV infection histories, 2022-23





Risk of dengue disease by prior DENV/ZIKV infection histories, 2004-23

#### Risk of dengue disease by preexisting DENV iELISA antibody titers, 2022-23



#### Mediation analysis with DENV iELISA titers between 10 and 320 (10< titers <= 320) as the mediator, 2022-23

Path Diagram







Mediation analysis with DENV iELISA titers above 320 (titers >320) as the mediator, 2022-23

Path Diagram

![](_page_49_Figure_7.jpeg)

![](_page_49_Figure_8.jpeg)

![](_page_49_Figure_9.jpeg)

В

Α

![](_page_50_Figure_0.jpeg)